<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01942070</url>
  </required_header>
  <id_info>
    <org_study_id>Ge IDE No. I01210</org_study_id>
    <nct_id>NCT01942070</nct_id>
  </id_info>
  <brief_title>A Prospective, Randomized Trial of BVS Veruss EES in Patients Undergoing Coronary Stenting for Myocardial Infarction</brief_title>
  <acronym>ISAR-Absorb MI</acronym>
  <official_title>Intracoronary Scaffold Assessment a Randomised Evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) A Prospective, Randomized Trial of BVS Veruss EES in Patients Undergoing Coronary Stenting for Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study is to test the clinical performance of the everolimus-eluting
      BVS compared with that of the durable polymer everolimus-eluting stent (EES) in patients
      undergoing PCI in the setting of acute MI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation currently
      represents the dominant treatment strategy in patients undergoing catheter intervention.
      However effective neointimal suppression occurs at the cost of a systematic delay in arterial
      healing in comparison with after bare metal stenting. This underlies a small but significant
      increased risk of stent thrombosis after DES implantation in comparison with bare metal stent
      implantation as well as a possible excess of in-stent neoatheroma formation.

      Bioresorbable vascular scaffolds (BVS) represent an innovative technology providing
      short-term vessel scaffolding and drug delivery without the long-term limitations of metallic
      DES and durable polymer coatings. Potential benefits include restoration of normal vasomotor
      reactivity, facilitation of positive vessel wall remodelling and facilitation of subsequent
      bypass grafting of the stented arterial segment. In addition preliminary reports suggest that
      the process of scaffold biodegradation may promote formation of a cohesive tissue layer
      covering and stabilizing the underlying atherosclerotic plaque - a so-called plaque-sealing
      effect. Although initial results with BVS are encouraging, there is a lack of randomized
      clinical trial data and no data exists for outcomes after BVS implantation in patients
      undergoing coronary stenting in the setting of acute myocardial infarction (MI).

      The aim of the current study is to test the clinical performance of the everolimus-eluting
      BVS compared with that of the durable polymer everolimus-eluting stent (EES) in patients
      undergoing PCI in the setting of acute MI. The primary endpoint will be percentage diameter
      stenosis at protocol-mandated 6-8 month angiographic follow-up. Sample size calculation is
      based on a non-inferiority assumption in relation to the BVS versus EES. It is planned to
      enrol a total of 260 patients. Subsequent clinical follow-up will be undertaken out to 5
      years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Diameter Stenosis</measure>
    <time_frame>6-8 months</time_frame>
    <description>Percentage diameter stenosis at coronary angiography at 6-8 months follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device-oriented composite endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of cardiac death/target vessel-myocardial infarction (MI)/ target lesion revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-oriented composite endpoint</measure>
    <time_frame>12 months</time_frame>
    <description>The composite of death/any MI/all revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of death or MI</measure>
    <time_frame>12 months</time_frame>
    <description>The composite of cardiovascular death or MI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>12 months</time_frame>
    <description>The incidence of scaffold or stent thrombosis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Thrombus</condition>
  <condition>Primary Angioplasty</condition>
  <arm_group>
    <arm_group_label>Bioresorbable vascular scaffold</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bioresorbable vascular scaffold (BVS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus-eluting stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Durable polymer everolimus-eluting metallic stent (EES)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bioresorbable vascular scaffold</intervention_name>
    <arm_group_label>Bioresorbable vascular scaffold</arm_group_label>
    <other_name>ABSORB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Durable polymer everolimus-eluting metallic stent</intervention_name>
    <arm_group_label>Everolimus-eluting stent</arm_group_label>
    <other_name>Xience</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 18 years or older with acute ST-elevation myocardial infarction or non
             ST-elevation myocardial infarction with angiographically confirmed thrombus

          2. Planned stent implantation in de novo lesions in native vessels or coronary bypass
             grafts with reference vessel diameter ≥2.5 mm and ≤3.9 mm

          3. Written, informed consent by the patient or her/his legally-authorized representative
             for participation in the study

          4. In women with childbearing potential a negative pregnancy test is mandatory

        Exclusion Criteria:

          1. Target lesion located in the left main trunk

          2. Severely calcified lesions

          3. Bifurcation lesions with side branch diameter &gt; 2mm

          4. In-stent restenosis

          5. Contraindications to antiplatelet therapy, cobalt chrome, everolimus, polylactic acid

          6. Malignancies or other comorbid conditions (for example severe liver, renal and
             pancreatic disease) with life expectancy less than 12 months or that may result in
             protocol non-compliance

          7. Pregnancy (present, suspected or planned) or positive pregnancy test.

          8. Previous enrolment in this trial

          9. Patient's inability to fully cooperate with the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A Byrne, MB PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Munich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert A Byrne, MB PhD</last_name>
    <phone>+49-89-1218</phone>
    <phone_ext>4587</phone_ext>
    <email>byrne@dhm.mhn.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Simon Schneider, MD</last_name>
    <phone>+49-89-4041</phone>
    <phone_ext>0</phone_ext>
    <email>simon-schneider@tum.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Munich</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert A Byrne, MD</last_name>
      <phone>+49-89-1218</phone>
      <phone_ext>4587</phone_ext>
      <email>byrne@dhm.mhn.de</email>
    </contact>
    <contact_backup>
      <last_name>ISAResearch Team</last_name>
      <phone>+49-89-1218</phone>
      <phone_ext>1534</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Robert A Byrne, MB PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts der Isar</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Schneider, MD</last_name>
      <phone>+49-89-4140</phone>
      <phone_ext>0</phone_ext>
      <email>simon-schneider@tum.de</email>
    </contact>
    <investigator>
      <last_name>Simon Schneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2013</study_first_submitted>
  <study_first_submitted_qc>September 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2013</study_first_posted>
  <last_update_submitted>October 30, 2013</last_update_submitted>
  <last_update_submitted_qc>October 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Bioresorbable vascular scaffold</keyword>
  <keyword>Durable polymer everolimus-eluting stent</keyword>
  <keyword>Primary angioplasty</keyword>
  <keyword>Stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

